Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers

Trial Profile

Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Zika virus vaccine-Themis (Primary)
  • Indications Zika virus infection
  • Focus Therapeutic Use
  • Sponsors Themis Bioscience
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
    • 01 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
    • 04 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top